Endocrine Abstracts

Introduction: Clinical trials indicate that Tolvaptan is safe and effective in the treatment of patients with sustained mild/moderate SIADH-induced euvolemic hyponatremia. Tolvaptan doses are often modified during chronic use. We present the weekly doses of a series of patients on chronic therapy, followed up in outpatient clinic.Methods: Retrospective, cross-sectional. 114 patients receiving tolvaptan for chronic SIADH were followed up in a Hyponatremia...